Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trials
Fred Yang,1 June Ye,2 Kenneth Pomerantz,3 Murray Stewart1 1Alternative Development Program, GlaxoSmithKline, King of Prussia, PA, 2Discovery Biometrics, GlaxoSmithKline, Research Triangle Park, NC, 3Clinical Development and Medical Affairs, Boehringer-Ingelheim Pharmaceuticals, Inc, Ridgefield, CT,...
Guardado en:
Autores principales: | Yang F, Ye J, Pomerantz K, Stewart M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/912265badf8e4dbb897f67b8f1ac6522 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluating the impact of type 2 diabetes mellitus on cardiovascular risk in persons with metabolic syndrome using the UKPDS risk engine
por: Ogedengbe OS, et al.
Publicado: (2015) -
Associations of Thyroid Hormone Levels and Macrovascular Complications in Euthyroid Type 2 Diabetic Patients
por: Hu Y, et al.
Publicado: (2021) -
The clinical utility of aflibercept for diabetic macular edema
por: Stewart MW
Publicado: (2015) -
Uncovering undetected hypoglycemic events
por: Unger J
Publicado: (2012) -
Difference Analysis Of Related Factors In Macrovascular And Microvascular Complications In Chinese Patients With Type 2 Diabetes Mellitus: A Case-Control Study Protocol
por: Zhao H, et al.
Publicado: (2019)